COVID-19 pneumonia in patients with underlying fatty liver

Not yet recruiting

• Conditions: Coronavirus as the cause of diseases classified elsewhere,

• Registration Number: CTRI/2022/03/040908
• Lead Sponsor: MAX Smart Super specialty Hospital A unit of Gujarmal Modi Hospital

Brief Summary

The Pandemic of COVID-19 has led to significant morbidity and mortality across the world since the early part of 2020. The Severe acute respiratory syndrome SARS CoV-2 primary affects the respiratory system and most deaths are related to the severe viral pneumonia and respiratory failure. However, other organ systems also seem to get affected to a variable degree. Patients who have underling co-morbidity seem to be more predisposed to worst outcomes. Almost 1/3rd to 3/4th of patients with COVID-19 have been reported to have some degree of liver injury at the time of presentation. Due to this patients with preexisting liver disease, especially those with cirrhosis have been reported to develop decompensation when they acquire infection with SARS-CoV-2. The data on the outcomes , especially mortality of COVID-19 among patient who have underlying fatty liver is limited and is fraught with ascertainment bias.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-15
• Last Update Posted: 2022-07-03

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• Patients who are positive for SARS CoV-2 nasopharyngeal swab RT-PCR 2.
• Patients with no history of underlying liver cirrhosis, fatty liver 3.
• Patients with no history of underlying liver cancer 4.
• Patients with no cardiac ailment 5.
• Patients with a CT severity score of > 1 6.
• Availability of upper abdominal cuts on the HRCT chest.

Exclusion Criteria

• Patients how are negative for SARS CoV-2 nasopharyngeal swab RT-PCR 2.
• Patients with known history of underlying cirrhosis.
• Patients with known history of underlying liver cancer 4.
• Patients with CHF 5.
• Patients with a CT severity score of < 1 6.
• Non-availability of upper abdominal cuts on the HRCT chest.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality rates of patients with COVID-19 pneumonia with underlying fatty liver	30 Days

Secondary Outcome Measures

Name	Time	Method
Morbidity rates of patients with COVID-19 pneumonia with underlying fatty liver.	The morbidity parameters to be studied are:

Trial Locations

Locations (1)

Max Smart Super Speciality Hospital A unit of Gujarmal Modi Hospital; 🇮🇳 South, DELHI, India

Max Smart Super Speciality Hospital A unit of Gujarmal Modi Hospital

🇮🇳South, DELHI, India

Dr Kaushal Madan

Principal investigator

9968407407

k_madan_2000@yahoo.com